Gilead Sciences Inc. (GILD)

69.12
0.47 0.68
NASDAQ : Health Technology
Prev Close 68.65
Open 69.24
Day Low/High 68.51 / 69.58
52 Wk Low/High 60.32 / 89.54
Volume 8.28M
Avg Volume 7.45M
Exchange NASDAQ
Shares Outstanding 1.29B
Market Cap 87.50B
EPS 3.50
P/E Ratio 54.11
Div & Yield 2.28 (3.33%)

Latest News

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Gilead Sciences To Present At The 37th Annual J.P. Morgan Healthcare Conference On Monday, January 7

Gilead Sciences To Present At The 37th Annual J.P. Morgan Healthcare Conference On Monday, January 7

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that members of the executive management team will participate in a fireside chat at the 37 th Annual J.

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

-- Agenus Webcast and Conference Call Scheduled for Today at 8:30a.m.ET --

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc.

Gilead Sciences And Scholar Rock Announce Strategic Collaboration To Develop Novel Therapies For Fibrotic Diseases

Gilead Sciences And Scholar Rock Announce Strategic Collaboration To Develop Novel Therapies For Fibrotic Diseases

Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta...

Stocks End Day in the Green as Dow, S&P Overcome Slow Starts

Stocks End Day in the Green as Dow, S&P Overcome Slow Starts

Stocks finished the day higher on Monday as gains by tech stocks offset concerns over the fate of U.S.-China trade talks, and after the U.K. delayed a parliamentary vote on Brexit.

Gilead Sciences Names Roche's O'Day as CEO and Chairman

Gilead Sciences Names Roche's O'Day as CEO and Chairman

Daniel O'Day will take over the helm of the biopharmaceutical giant on March 1, 2019.

3 Profitable Small Biotech Names to Consider

3 Profitable Small Biotech Names to Consider

Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.

Elon Musk, Carlos Ghosn, Huawei and Gilead Sciences - 5 Things You Must Know

Elon Musk, Carlos Ghosn, Huawei and Gilead Sciences - 5 Things You Must Know

U.S. stock futures turn mixed as investors continue to express concerns over the fate of U.S.-China trade talks; Tesla's Elon Musk says, 'I do not respect the SEC'; Carlos Ghosn and Nissan are indicted in Japan for underreporting the former chairman's pay.

Gilead Sciences Names Daniel O'Day Chairman And Chief Executive Officer

Gilead Sciences Names Daniel O'Day Chairman And Chief Executive Officer

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its Board of Directors has named Daniel O'Day Chairman of the Board and Chief Executive Officer, effective March 1, 2019.

China's National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) For Treatment Of Chronic Hepatitis C Virus Genotype 1-6

China's National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) For Treatment Of Chronic Hepatitis C Virus Genotype 1-6

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the National Medical Products Administration (NMPA) has approved Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) in China for the treatment of chronic hepatitis C virus (HCV) genotype 1-6 infection...

China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 Infection

China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 Infection

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the China National Medical Products Administration (NMPA) has approved Descovy ® (emtricitabine 200 mg/tenofovir alafenamide 10 mg and emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a...

Kite Announces Updated Data From ZUMA-3 Study Of KTE-X19 In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Kite Announces Updated Data From ZUMA-3 Study Of KTE-X19 In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Kite, a Gilead Company (Nasdaq: GILD), announced updated results from ZUMA-3, a single-arm Phase 1/2 study evaluating KTE-X19 (formerly KTE-C19), an investigational CD19 chimeric antigen receptor T (CAR T) cell therapy, in adult patients with relapsed or...

Kite Announces Two-Year Data For Yescarta® (Axicabtagene Ciloleucel) In Patients With Refractory Large B-Cell Lymphoma

Kite Announces Two-Year Data For Yescarta® (Axicabtagene Ciloleucel) In Patients With Refractory Large B-Cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), announced two-year efficacy and safety data from the pivotal ZUMA-1 trial of Yescarta ® (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.

China National Medical Products Administration (NMPA) Approves Gilead's Vemlidy® (Tenofovir Alafenamide) For Chronic Hepatitis B Virus (HBV) Infection

China National Medical Products Administration (NMPA) Approves Gilead's Vemlidy® (Tenofovir Alafenamide) For Chronic Hepatitis B Virus (HBV) Infection

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Medical Products Administration (NMPA) has approved Vemlidy ® (tenofovir alafenamide, TAF) 25 mg, a once-daily treatment for chronic hepatitis B in adults and adolescents (aged...

Gilead Sciences To Present At The Evercore ISI HealthCONx Conference On Tuesday, November 27

Gilead Sciences To Present At The Evercore ISI HealthCONx Conference On Tuesday, November 27

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L.

Gilead Presents Latest Data From Viral Hepatitis Research Programs At The Liver Meeting® 2018

Gilead Presents Latest Data From Viral Hepatitis Research Programs At The Liver Meeting® 2018

Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from studies investigating Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg) in chronic hepatitis C virus (HCV) infected patients with severe renal impairment undergoing dialysis and Harvoni ®...

Gilead Announces Positive Phase 2 Results For GS-9674 In Primary Sclerosing Cholangitis (PSC) At The Liver Meeting® 2018

Gilead Announces Positive Phase 2 Results For GS-9674 In Primary Sclerosing Cholangitis (PSC) At The Liver Meeting® 2018

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that treatment with GS-9674, an investigational, selective, nonsteroidal farnesoid X receptor (FXR) agonist, led to significant improvements in liver biochemistry and markers of cholestasis in patients...

Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program For Advanced Fibrosis At The Liver Meeting® 2018

Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program For Advanced Fibrosis At The Liver Meeting® 2018

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the company's clinical development program for advanced fibrosis due to nonalcoholic steatohepatitis (NASH).

Gilead Sciences Is Sporting a Bearish Set of Charts for Investors

Gilead Sciences Is Sporting a Bearish Set of Charts for Investors

Gilead has been trying to turn things around but few see that turn coming anytime soon.

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.

Gilead To Present Latest Scientific Research In Hematologic Malignancies And Solid Tumors At ASH 2018

Gilead To Present Latest Scientific Research In Hematologic Malignancies And Solid Tumors At ASH 2018

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from its oncology and cell therapy research programs will be presented at the 60 th American Society of Hematology (ASH) Annual Meeting & Exposition, in San Diego from December 1 - 4, 2018.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Gilead Sciences And Tango Therapeutics Announce Strategic Collaboration To Develop Next-Generation Targeted Immuno-Oncology Therapies

Gilead Sciences And Tango Therapeutics Announce Strategic Collaboration To Develop Next-Generation Targeted Immuno-Oncology Therapies

Gilead Sciences, Inc. (Nasdaq: GILD) and Tango Therapeutics, Inc.

Gilead Announces 96-Week Results From Phase 3 Study Of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 In Adults New To HIV Therapy

Gilead Announces 96-Week Results From Phase 3 Study Of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 In Adults New To HIV Therapy

Gilead Sciences, Inc. (Nasdaq: GILD) today announced 96-week results from a Phase 3, randomized, double-blinded study (Study 1490) evaluating the safety and efficacy of Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg...

Be Ready to Ride the Dividend on Gilead Sciences

Be Ready to Ride the Dividend on Gilead Sciences

There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.

TheStreet Quant Rating: C (Hold)